News | Pharmaceuticals | December 11, 2018

Nationwide Recall of Valsartan Blood Pressure Medication Expanded

Mylan recall initiated due to trace amounts of an impurity classified as a probable human carcinogen

Mylan Expands Nationwide Recall of Valsartan Blood Pressure Medication

December 11, 2018 — Mylan Pharmaceuticals is expanding its consumer-level voluntary nationwide recall to include all lots of products containing Valsartan within expiry due to an impurity that has been classified as a probable human carcinogen. Valsartan is used for the treatment of high blood pressure for the treatment of heart failure, and to reduce cardiovascular mortality following myocardial infarction.

The 104 additional lots include:

  • Twenty-six (26) lots of Amlodipine and Valsartan Tablets, USP (including the 5mg/160mg, 10mg/160mg, 5mg/320mg and 10mg/320mg strengths);

  • Fifty-one (51) lots of Valsartan Tablets, USP (including 40 mg, 80 mg, 160 mg and 320 mg strengths); and

  • Twenty-seven (27) lots of Valsartan and Hydrochlorothiazide Tablets, USP (80mg/12.5mg, 160mg/12.5mg, 160mg/25mg, 320mg/12.5mg and 320mg/25mg strengths).

Valsartan in combination with amlodipine or hydrochlorothiazide is used for the treatment of high blood pressure. Patients should contact their pharmacist or physician who can advise them about an alternative treatment prior to returning their medication. Patients who are on valsartan should continue taking their medication, as the risk of harm to the patient’s health may be higher if the treatment is stopped immediately without any alternative treatment.

These products are being recalled due to detected trace amounts of an impurity, N-nitrosodiethylamine (NDEA) contained in the API Valsartan, USP, manufactured by Mylan Laboratories Ltd. NDEA is a substance that occurs naturally in certain foods, drinking water, air pollution and industrial processes, and has been classified as a probable human carcinogen according to the International Agency for Research on Cancer (IARC).

The finished products are manufactured by Mylan Pharmaceuticals Inc. and Mylan Laboratories Ltd. These batches were distributed in the U.S. between March 2017 and November 2018.   

Mylan is notifying its distributors and customers by letter and is arranging for return of all recalled products. Wholesalers, retailers and consumers that are in possession of recalled product should contact Stericycle at 1-888-406-9305 for the return of the recalled product. Normal business hours are Monday through Friday 8 a.m. to 5 p.m. EST.

Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to using these drug products.

  • Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax. Complete and submit the report Online: www.fda.gov/medwatch/report.htm

  • Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form or submit by fax to 1-800-FDA-0178.

The full expanded list of recalled batches can be seen here.

For more information: www.fda.gov

 

Related Content

News | Hypertension

November 23, 2022 — In 2015, published findings from the landmark Systolic Blood Pressure Intervention Trial (SPRINT) ...

Home November 23, 2022
Home
News | Hypertension

November 21, 2022 — Mineralys Therapeutics, Inc., a private, clinical-stage biopharmaceutical company committed to ...

Home November 21, 2022
Home
News | Hypertension

November 21, 2022 — Mineralys Therapeutics, Inc., a private, clinical-stage biopharmaceutical company committed to ...

Home November 21, 2022
Home
News | Hypertension

November 9, 2022 — CinCor Pharma, Inc. announced the presentation today of Phase 2 data from its BrigHtn trial as part ...

Home November 09, 2022
Home
News | Hypertension

October 24, 2022 — CinCor Pharma, Inc. announced the publication of Phase 1 clinical data for baxdrostat, a highly ...

Home October 24, 2022
Home
News | Hypertension

October 5, 2022 — CinCor Pharma, Inc. (NASDAQ: CINC) today announced that the company will present Phase 2 data from its ...

Home October 05, 2022
Home
News | Hypertension

September 26, 2022 — ReCor Medical, Inc., a wholly owned subsidiary of Otsuka Medical Devices Co., Ltd., announced the ...

Home September 26, 2022
Home
News | Hypertension

September 20, 2022 — Orchestra BioMed, Inc., a biomedical innovation company accelerating high-impact technologies to ...

Home September 20, 2022
Home
News | Hypertension

September 12, 2022 — Researchers at the National Institutes of Health have found that a novel blood test can be used to ...

Home September 12, 2022
Home
News | Hypertension

August 8, 2022 — Cardiovascular diseases remain a leading cause of death around the world. A primary contributor to ...

Home August 08, 2022
Home
Subscribe Now